Strategic funding of 1,8M€ elevating Spanish research infrastructure to forge a path of innovation and resilience.
March 19th 2024, NANBIOSIS
As already announced at the end of last year, from NANBIOSIS we are poised for a groundbreaking leap forward thanks to a 1,800,000€ injection of European funding. This funding has recently materialized in a significant improvement and update of the equipment and services of NANBIOSIS Units.
The Spanish Government’s Recovery, Transformation, and Resilience Plan (Plan de Recuperación, Transformación y Resiliencia – PRTR) stands as a beacon of hope amid the challenges brought forth by the COVID-19 crisis. This comprehensive roadmap not only charts a course for the modernization of the Spanish economy but also envisions a resilient and inclusive reconstruction post-pandemic.
In alignment with these objectives, the Spanish Ministry of Science and Innovation has announced substantial funding aimed at bolstering the Unique Scientific and Technical Infrastructures (ICTS) with a staggering amount granted to NANBIOSIS Units. This strategic investment serves as a testament to Spain’s commitment to fostering excellence in research and innovation, particularly in the realm of nanomedicine, biomaterials, and biomedical systems.
This initiative (…) has been allocated 1,800,000€ funding from the Next Generation EU funds, marking a pivotal moment in Spain’s scientific landscape.
One notable project, ICT2021-006987, spearheads the drive towards a new era of infrastructure designed to facilitate the production and preclinical characterization of advanced therapeutics and diagnostic tools. This initiative, championed by the CIBER node of NANBIOSIS, has been allocated 1,800,000€ funding from the Next Generation EU funds, marking a pivotal moment in Spain’s scientific landscape.
The impact of this investment reverberates across various facets of NANBIOSIS’ operations, with specific allocations directed towards enhancing research capabilities in critical areas. Maintenance, improvement, and acquisition of cutting-edge equipment across multiple NANBIOSIS Units will enable advancements in hybridoma development, immunochemistry, high-performance liquid chromatography, fluorescence analysis, and more.
By aligning with international standards and best practices, NANBIOSIS strengthens its position as a hub of scientific excellence with global relevance.
Notably, the acquisition of a MicroCT system for NANBIOSIS U13 and an MRI equipment scanner for NANBIOSIS U26 underscores Spain’s commitment to staying at the forefront of technological innovation in the biomedical field. These state-of-the-art instruments not only empower researchers with unprecedented capabilities but also pave the way for groundbreaking discoveries in areas such as tissue engineering, drug development, and precision medicine. In addition, by aligning with international standards and best practices, NANBIOSIS strengthens its position as a hub of scientific excellence with global relevance.
To see the full list of equipment and how the aforementioned funding has been allocated among our Units, visit here.
Looking ahead, the infusion of funds into NANBIOSIS projects represents just the beginning of a transformative journey towards a more resilient and innovative Spain.
In conclusion, the support extended to NANBIOSIS through the Recovery, Transformation, and Resilience Plan heralds a new era of possibilities for Spanish research and innovation. By investing in cutting-edge infrastructure and research capabilities, Spain reaffirms its commitment to shaping a brighter future for generations to come.
Related News:
About NANBIOSIS:
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions, place your request here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
